We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
We created FlyFit with the aim to change the way people travel. Air travel can be stressful, lonely, and unhealthy. On top of this, with average layovers of 2+ hours, flight delays, and hours waiting in security, there is too much unproductive time in airports with limited healthy options to choose from.
days to go: Expired investment: £500,060
Felcana is a patented Eco-system of connected devices: Helix, Home Hub, Micro-Location Beacons and the Felcana application which work together to monitor the pet's (cat or dogs) well-being. This Digital Pet Health Platform tracks pet's behaviour and provides the vet, rich data leading to faster diagnosis and faster treatment. Felcana has been developed by a world-class team of vets and engineers and, it has been designed and tested by using the latest materials, designs, and techniques. Felcana has won the Design Spark Award in 2017. It is making unique partnerships with leading pet industries and the UK's largest pet health plan provider, the world's top-ranked vet school and The Royal Veterinary College. The new investment will enable it to grow consumer reach and accelerate its sales.
days to go: Expired investment: £343,926
DNApal is a personalised diet, health and fitness app that combines DNA infomation with other factors like age, weight, diet, family history and health goals. Two of the largest consumer DNA companies, 23andMe and Ancestry.com, have tested over 18m people. DNApal is capable of interpreting DNA results from these companies to provide precise recommendations on how to improve diet, hormone balance, weight loss, sleep, fitness & more. The company also won the best pitch at VentureFest 2019 at Oxford Brookes University. DNApal is aiming to launch MVP in January 2020 (iOS). The company is also aiming to recommend further testing and specific supplements where necessary and offer 1:1 consultations with a specialist. With the fund raised, DNApal plans to develop the full scope of the app, weekly goals, content challenges to keep users committed.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £49,990
EasyGym operates an international, low-cost, fast-growing, big-box gym franchise network. While working with 6 countries and more than 250 sites, easyGym is growing rapidly with its franchise system and cloud-based technology. It is aiming to provide people with access to high-quality gyms that are open 24/7. The company aims to use its recurring revenue to develop a sustainable business platform capable to drive innovation, generate investment value, and support global expansion. With the proceeds, easyGym will build the biggest global fitness network by 2030. 50% of its proceeds will be used to create a corporate hub in London, 17% will be used in Franchise Marketing, and 33% will be used for Technology and Support.
days to go: Expired investment: £828,357
Yapa® is a free social app with an emphasis on your mental health. The application gives a solution to the users to have accurate changes in both mental illness and mental wellness. The application has exceeded 10,000 downloads, and it has 400,000 followers. It has elected former England and Liverpool FC goalkeeper Chris Kirkland as the first ambassador to encourage and build Yapa. The funds will be used for marketing, operation and product innovation.
days to go: Expired investment: £41,930
Future You Cambridge is a company that sells clinically proven health supplements directly to consumers. Since its launch in 2016, it has sold products to over 100,000 customers. The company's Lactolycopene product received a patent in December 2017 and its Fertility+ product was also covered by the European Journal of Nutrition in a clinical paper and was shown to have resulted in a 40% increase in male fertility. The company's offerings now stand at 24 products, including the popular CBD product and its first product for pets, Curcupet-K9. Additionally, the company won the 2018 Cambridge Service Excellence and Independent High Growth Business of the Year Awards and has 5-star ratings on Trustpilot. They will use the investment to scale up direct advertising campaigns, expand its product range by more than 10 new products, and invest in their website to make it more intuitive.

Pitch Rated

67%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £655,011
A personal fitness app that aims to provide affordable and accessible training on demand. Auro offers classes for specific needs via an audio coach; from increasing stamina, to losing weight. Each class includes a motivational trainer with a dedicated playlist. The company also utilises artificial intelligence to personalise workout programmes for each user and has filed a patent for this technology. Auro’s app has already received more than 10k downloads and is backed by top investors, such as the founders of LoveFilm, Zoopla and Passion Capital. The company is raising funds to scale the business further in the UK and expand into Europe.
days to go: Expired investment: £262,230
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph